Broad-spectrum chemokine inhibition reduces vascular macrophage accumulation and collagenolysis consistent with plaque stabilization in mice

Journal of Vascular Research

Volumn 42, Issue 6, 2005, Pages 492-502

  Reckless, Jill ^a   Tatalick, Laurie ^b   Wilbert, Sybille ^b   McKilligin, Elaine ^a   Grainger, David J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Poniard Pharmaceuticals Inc   (United States)

Author keywords

apoE deficient mice; Atherosclerosis; Inflammation; Quantitative immunofluorescence

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; NR 583143; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; COLLAGEN SYNTHESIS; CONTROLLED STUDY; GENETIC ANALYSIS; IMMUNOHISTOCHEMISTRY; LIPID ANALYSIS; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD11B; AORTA; APOLIPOPROTEINS E; CHEMOKINES; COLLAGEN; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PEPTIDES, CYCLIC; STAINING AND LABELING;

EID: 27344458905     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088139     Document Type: Article

References (31)

1. Gronholdt ML, Dalager-Pedersen S, Falk E: Coronary atherosclerosis: determinants of plaque rupture. Eur Heart J 1998;19(suppl C):C24-C29.
2. Felton CV, Crook D, Davies MJ, et al: Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997;17:1337-1345.
3. Lendon CL, Davies MJ, Born GV, et al: Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991;87:87-90.
4. Loree HM, Tobias BJ, Gibson LJ, et al: Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb 1994;14:230-234.
5. Sukhova GK, Schonbeck U, Rabkin E, et al: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-2509.
6. Libby P, Geng YJ, Aikawa M, et al: Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996;7:330-335.
7. Reckless J, Rubin EM, Verstuyft JB, et al: Monocyte chemoattractant protein-1 but not tumor necrosis factor-alpha is correlated with monocyte infiltration in mouse lipid lesions. Circulation 1999;99:2310-2316.
8. Lawn RM, Pearle AD, Kunz LL, et al: Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996;271:31367-31371.
9. Nelken NA, Coughlin SR, Gordon D, et al: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-1127.
10. Yu X, Dluz S, Graves DT, et al: Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992;89:6953-6957.
11. Dawson TC, Kuziel WA, Osahar TA, et al: Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999;143:205-211.
12. Boring L, Gosling J, Cleary M, et al: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-897.
13. Gosling J, Slaymaker S, Gu L, et al: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999;103:773-778.
14. Gu L, Okada Y, Clinton SK, et al: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-281.
15. Aiello RJ, Bourassa PA, Lindsey S, et al: Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999;19:1518-1525.
16. Reckless J, Grainger DJ: Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines. Biochem J 1999;340:803-811.
17. Reckless J, Tatalick LM, Grainger DJ: The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leukocyte recruitment induced by lipopolysaccharide in vivo. Immunology 2001;103:244-254.
18. Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SCR, Menon DK: Neuroprotection in ischaemia reperfusion injury: an anti-inflammatory approach using a novel broad-spectrum chemokine inhibitor. J Cereb Blood Flow Metab 2001;21:683-689.
19. Naidu BV, Farivar AS, Woolley SM, et al: Novel broad-spectrum chemokine inhibitor protects against lung ischemia-reperfusion injury. J Heart Lung Transplant 2004;23:128-134.
20. Grainger DJ, Reckless J, McKilligin E: Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 2004;173:6366-6375.
21. Reckless J, Metcalfe JC, Grainger DJ: Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997;95:1542-1548.
22. Paigen B, Morrow A, Holmes PA, et al: Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987;68:231-240.
23. Mosedale DE, Metcalfe JC, Grainger DJ: Optimization of immunofluorescence methods by quantitative image analysis. J Histochem Cytochem 1996;44:1043-1050.
24. Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC, Grainger DJ: A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions. J Vasc Res 2001;38:256-265.
25. Grainger DJ, Metcalfe JC, Grace AA, et al: Transforming growth factor-beta dynamically regulates vascular smooth muscle differentiation in vivo. J Cell Sci 1998;111:2977-2988.
26. Zisman DA, Kunkel SL, Strieter RM, et al: MCP-1 protects mice in lethal endotoxemia. J Clin Invest 1997;99:2832-2836.
27. Hayes IM, Jordan NJ, Towers S, et al: Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 1998;18:397-403.
28. Porreca E, Di Febbo C, Reale M, et al: Monocyte chemotactic protein 1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells. J Vasc Res 1997;34:58-65.
29. Rekhter MD, Hicks GW, Brammer DW, et al: Animal model that mimics atherosclerotic plaque rupture. Circ Res 1998;83:705-713.
30. Weissberg P: Mechanisms modifying atherosclerotic disease - From lipids to vascular biology. Atherosclerosis 1999;147(suppl 1):S3-S10.
31. Aengevaeren WR, Uijen GJ, Jukema JW, et al: Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1997;96:429-435.